{"id":1089,"date":"2021-03-11T17:50:29","date_gmt":"2021-03-11T16:50:29","guid":{"rendered":"https:\/\/dose-innova.ccoo.cat\/?p=1089"},"modified":"2021-03-12T18:11:46","modified_gmt":"2021-03-12T17:11:46","slug":"aportacion-minusvalidos-2","status":"publish","type":"post","link":"https:\/\/ccoo.app\/towa-pharmaceutical-europe\/aportacion-minusvalidos-2\/","title":{"rendered":"Aportaci\u00f3n minusvalidos"},"content":{"rendered":"\n<p><strong>Percepci\u00f3n de un importe de&nbsp;389,10 euros mensuales<\/strong>,&nbsp;para aquellos empleados que tengan hijos con una minusvalia reconocida por el IMSERSO o por el \u00f3rgano competente de su Comunidad Aut\u00f3noma en materia de valoraci\u00f3n de minusval\u00edas..<\/p>\n\n\n\n<p>Esta percepci\u00f3n es independiente de los niveles salariales.<\/p>\n\n\n\n<p>El abono se efect\u00faa a trav\u00e9s de la n\u00f3mina.<\/p>\n\n\n\n<p><strong>Requisitos:<\/strong> tendr\u00e1 que acreditarse mediante entrega al Departamento de Recursos Humanos del documento declarativo de la condici\u00f3n oficial de discapacidad<\/p>\n    \t","protected":false},"excerpt":{"rendered":"<p>Percepci\u00f3n de un importe de&nbsp;389,10 euros mensuales,&nbsp;para aquellos empleados que tengan hijos con una minusvalia reconocida por el IMSERSO o por el \u00f3rgano competente de su Comunidad Aut\u00f3noma en materia &#8230; <a title=\"Aportaci\u00f3n minusvalidos\" class=\"read-more\" href=\"https:\/\/ccoo.app\/towa-pharmaceutical-europe\/aportacion-minusvalidos-2\/\" aria-label=\"Leer m\u00e1s sobre Aportaci\u00f3n minusvalidos\">Leer m\u00e1s<\/a><\/p>\n","protected":false},"author":59,"featured_media":1091,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[14],"tags":[],"class_list":["post-1089","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-beneficissocials","generate-columns","tablet-grid-50","mobile-grid-100","grid-parent","grid-33"],"_links":{"self":[{"href":"https:\/\/ccoo.app\/towa-pharmaceutical-europe\/wp-json\/wp\/v2\/posts\/1089","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ccoo.app\/towa-pharmaceutical-europe\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ccoo.app\/towa-pharmaceutical-europe\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ccoo.app\/towa-pharmaceutical-europe\/wp-json\/wp\/v2\/users\/59"}],"replies":[{"embeddable":true,"href":"https:\/\/ccoo.app\/towa-pharmaceutical-europe\/wp-json\/wp\/v2\/comments?post=1089"}],"version-history":[{"count":1,"href":"https:\/\/ccoo.app\/towa-pharmaceutical-europe\/wp-json\/wp\/v2\/posts\/1089\/revisions"}],"predecessor-version":[{"id":3273,"href":"https:\/\/ccoo.app\/towa-pharmaceutical-europe\/wp-json\/wp\/v2\/posts\/1089\/revisions\/3273"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ccoo.app\/towa-pharmaceutical-europe\/wp-json\/wp\/v2\/media\/1091"}],"wp:attachment":[{"href":"https:\/\/ccoo.app\/towa-pharmaceutical-europe\/wp-json\/wp\/v2\/media?parent=1089"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ccoo.app\/towa-pharmaceutical-europe\/wp-json\/wp\/v2\/categories?post=1089"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ccoo.app\/towa-pharmaceutical-europe\/wp-json\/wp\/v2\/tags?post=1089"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}